The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
作者： Jing Huang , Lei Wang , Zhongyi Cong , Zohreh Amoozgar , Evgeny Kiner
DOI: 10.1016/J.BBRC.2015.05.083
关键词:
摘要: … Brca1 −/− murine ovarian cancer cell line BR5FVB1-Akt, … ovarian cancer. With this model, we provide the first in vitro and in vivo analysis of BMN 673 function in a murine ovarian cancer …
elsevier.com
core.ac.uk 
sci-hub.se 参考文章(24)
Mary Leung, David Rosen, Scott Fields, Alessandra Cesano, Daniel R Budman, Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Molecular Medicine. ,vol. 17, pp. 854- 862 ,(2011) , 10.2119/MOLMED.2010.00240
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, M. J. Thun, Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. ,vol. 57, pp. 43- 66 ,(2007) , 10.3322/CANJCLIN.57.1.43
Claudia Marchetti, Ludovica Imperiale, Maria Luisa Gasparri, Innocenza Palaia, Sandro Pignata, Terenzio Boni, Filippo Bellati, Pierluigi Benedetti Panici, Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs. ,vol. 21, pp. 1575- 1584 ,(2012) , 10.1517/13543784.2012.707189
Edward R. Kost, David G. Mutch, Thomas J. Herzog, Interferon-γ and Tumor Necrosis Factor-α Induce Synergistic Cytolytic Effects in Ovarian Cancer Cell Lines—Roles of the TR60 and TR80 Tumor Necrosis Factor Receptors☆ Gynecologic Oncology. ,vol. 72, pp. 392- 401 ,(1999) , 10.1006/GYNO.1998.5257
Markéta Tomšová, Bohuslav Melichar, Iva Sedláková, Ivo Šteiner, Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecologic Oncology. ,vol. 108, pp. 415- 420 ,(2008) , 10.1016/J.YGYNO.2007.10.016
Zev A. Wainberg, Johann S. de Bono, Lida Mina, Jasgit Sachdev, Lauren Averett Byers, Rashmi Chugh, Charlie Zhang, Joshua W. Henshaw, Andrew Dorr, John Glaspy, Ramesh Ramanathan, Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. Molecular Cancer Therapeutics. ,vol. 12, ,(2013) , 10.1158/1535-7163.TARG-13-C295
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S. Ho, Martin L. Miller, Natasha Rekhtman, Andre L. Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan, Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Science. ,vol. 348, pp. 124- 128 ,(2015) , 10.1126/SCIENCE.AAA1348
Christopher J. Lord, Alan Ashworth, The DNA damage response and cancer therapy Nature. ,vol. 481, pp. 287- 294 ,(2012) , 10.1038/NATURE10760
Deyin Xing, Sandra Orsulic, A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma Cancer Research. ,vol. 66, pp. 8949- 8953 ,(2006) , 10.1158/0008-5472.CAN-06-1495
Haifeng Qiu, Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--letter. Clinical Cancer Research. ,vol. 20, pp. 2236- 2236 ,(2014) , 10.1158/1078-0432.CCR-13-2679